Newamsterdam Pharma Stock Fundamentals
| NAMSW Stock | 9.06 0.63 6.50% |
NewAmsterdam Pharma fundamentals help investors to digest information that contributes to NewAmsterdam Pharma's financial success or failures. It also enables traders to predict the movement of NewAmsterdam Stock. The fundamental analysis module provides a way to measure NewAmsterdam Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NewAmsterdam Pharma stock.
At this time, NewAmsterdam Pharma's Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 11.8 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 94 M in 2024. NewAmsterdam | Select Account or Indicator |
NewAmsterdam Pharma Company Return On Equity Analysis
NewAmsterdam Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current NewAmsterdam Pharma Return On Equity | -0.47 |
Most of NewAmsterdam Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NewAmsterdam Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
NewAmsterdam Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, NewAmsterdam Pharma has a Return On Equity of -0.4737. This is 98.02% lower than that of the Biotechnology sector and 98.7% lower than that of the Health Care industry. The return on equity for all United States stocks is 52.81% higher than that of the company.
NewAmsterdam Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NewAmsterdam Pharma's current stock value. Our valuation model uses many indicators to compare NewAmsterdam Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NewAmsterdam Pharma competition to find correlations between indicators driving NewAmsterdam Pharma's intrinsic value. More Info.NewAmsterdam Pharma is regarded third in return on equity category among its peers. It also is regarded third in return on asset category among its peers . At this time, NewAmsterdam Pharma's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NewAmsterdam Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NewAmsterdam Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewAmsterdam Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics of similar companies.NewAmsterdam Pharma is currently under evaluation in return on equity category among its peers.
NewAmsterdam Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NewAmsterdam Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NewAmsterdam Pharma's managers, analysts, and investors.Environmental | Governance | Social |
NewAmsterdam Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Number Of Shares Shorted | 3.47 K | ||||
| Revenue | 12.76 M | ||||
| EBITDA | (176.86 M) | ||||
| Net Income | (160.27 M) | ||||
| Total Debt | 60 K | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (141.22 M) | ||||
| Number Of Employees | 62 | ||||
| Beta | -0.001 | ||||
| Total Asset | 347.1 M | ||||
| Retained Earnings | (316.97 M) | ||||
| Working Capital | 296.89 M | ||||
| Net Asset | 347.1 M |
About NewAmsterdam Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 8.9 M | 9.4 M | |
| Total Revenue | 12.8 M | 12.1 M | |
| Cost Of Revenue | 44.4 K | 47.5 K | |
| Stock Based Compensation To Revenue | 0.04 | 0.03 | |
| Sales General And Administrative To Revenue | 1.81 | 1.61 | |
| Research And Ddevelopement To Revenue | 12.49 | 13.12 | |
| Revenue Per Share | 0.16 | 0.15 | |
| Ebit Per Revenue | (12.99) | (13.63) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.